Boom in weight-loss drugs could lead to drop in beer sales, Heineken warns British pubs
Summary
Heineken has warned that the growing use of weight-loss drugs called GLP-1s, like Ozempic and Wegovy, may reduce alcohol drinking in British pubs. This could lead to fewer pints sold and changes in how people buy drinks, such as choosing smaller or lower-alcohol options.Key Facts
- GLP-1 drugs, used for weight loss, are becoming very popular and may lower people’s desire to drink alcohol.
- Heineken, the world’s second largest beer maker, shared a report with UK pubs about this trend.
- The company advised pubs to offer half-pints, low- or no-alcohol drinks, and small food portions to keep customers.
- About 10 million people in the US used GLP-1 weight-loss drugs last year.
- Heineken noted that drinkers on GLP-1 drugs tend to buy smaller servings, lower alcohol drinks, and more premium products.
- Beer sales in British pubs and bars totaled nearly £14 billion in a recent year, with only a small part from low-alcohol options.
- Other brewers like Diageo and Carlsberg say the impact of these drugs on beer sales is still unclear or manageable.
- Research surveys also show that GLP-1 users often reduce their alcohol consumption.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
